Package Leaflet: Information for the User
Solifenacin Novalie 5 mg film-coated tablets EFG
Solifenacin, succinate
Read the package leaflet carefully before starting to take this medicine because it contains important information for you.
Contents of the package leaflet
The active substance in Solifenacin Novalie belongs to the group of anticholinergics. These medicines are used to reduce the activity of the overactive bladder. This allows you to have more time before you need to urinate and increases the amount of urine that your bladder can hold.
Solifenacin Novalie is used to treat the symptoms of overactive bladder syndrome. These symptoms include: having a strong and sudden need to urinate without prior warning, having to urinate frequently or having urine leaks because you cannot get to the toilet in time.
Do not take Solifenacin Novalie
Before starting treatment with solifenacin, inform your doctor if you have or have had any of the above-mentioned diseases.
Warnings and precautions
Talk to your doctor or pharmacist before starting to take this medicine.
Children and adolescents
This medicine must not be used in children and adolescents under 18 years.
Tell your doctor before starting treatment with this medicine if any of the above circumstances have ever occurred to you.
Before starting treatment with solifenacin, your doctor will assess whether there are other causes for your frequent need to urinate (e.g. heart failure or kidney disease). If you have a urinary tract infection, your doctor will prescribe an antibiotic (treatment against certain bacterial infections).
Using Solifenacin Novalie with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines. It is especially important to inform your doctor if you are taking:
Using Solifenacin Novalie with food, drinks, and alcohol
This medicine can be taken with or without food, as you prefer.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Do not use solifenacin if you are pregnant unless it is absolutely necessary.
Do not use solifenacin during breastfeeding, as solifenacin may pass into breast milk.
Driving and using machines
Solifenacin may cause blurred vision and sometimes drowsiness or fatigue. If you experience any of these side effects, do not drive or use machines.
Solifenacin Novalie contains lactose
This medicine contains lactose. If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
Instructions for correct use
Follow exactly the administration instructions of this medicine given by your doctor. If you are in doubt, consult your doctor or pharmacist again.
Swallow the tablet whole with some liquid. It can be taken with or without food, as you prefer. Do not crush the tablets.
The recommended dose is 5 mg per day, unless your doctor tells you to take 10 mg per day.
If you take more Solifenacin Novalie than you should
In case of overdose or accidental ingestion, contact your doctor or pharmacist immediately, or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount taken.
The symptoms in case of overdose may include: headache, dry mouth, dizziness, drowsiness, and blurred vision, perception of things that are not there (hallucinations), pronounced excitement, convulsions, difficulty breathing, increased heart rate (tachycardia), accumulation of urine in the bladder (urinary retention), and dilation of the pupils (mydriasis).
If you forget to take Solifenacin Novalie
If you forget to take a dose at the usual time, take it as soon as you remember, unless it is time to take the next dose. Never take more than one dose per day. If you are in doubt, consult your doctor or pharmacist.
If you stop taking Solifenacin Novalie
If you stop taking solifenacin, your overactive bladder symptoms may return or worsen. Always consult your doctor if you are thinking of stopping treatment.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you suffer an allergic attack or a severe skin reaction (e.g. blistering and peeling of the skin), you should inform your doctor or nurse immediately.
Angioedema (allergy in the skin that results in inflammation that occurs in the tissue under the skin surface) with respiratory tract obstruction (difficulty breathing) has been reported in some patients treated with solifenacin succinate. If angioedema appears, treatment with solifenacin succinate should be discontinued immediatelyand appropriate treatment and/or measures should be taken.
Solifenacin may cause the following side effects:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Rare side effects (may affect up to 1 in 1,000 people)
Very rare side effects (may affect up to 1 in 10,000 people)
Frequency not known (frequency cannot be estimated from the available data)
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this package leaflet. You can also report side effects directly through the Spanish Medicines Vigilance System for Human Use. Website: www.notificaRAM.es.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
This medicine does not require any special storage conditions.
Do not use Solifenacin Novalie after the expiry date which is stated on the packaging. The expiry date is the last day of the month stated.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Solifenacin Novalie
Appearance of the product and pack contents
Solifenacin Novalie 5 mg is presented in the form of film-coated tablets, round, yellow, and with the inscription "E2" on one side.
Solifenacin Novalie 5 mg film-coated tablets are available in packs of 30 tablets.
Marketing authorisation holder
Novalie Pharma, S.L.U.
Calle Jorge Ruiz de Santallana, 51
05005 Ávila, España
Manufacturer
Neuraxpharm Pharmaceuticals, S.L.
Avda. Barcelona 69
08970 Sant Joan Despí (Barcelona), España
This medicine is authorised in the following countries:
Netherlands Solifenacinesuccinaat Lesvi 5 mg filmomhulde tabletten
Poland Soreca
Spain Solifenacina Novalie 5 mg comprimidos recubiertos con película
Date of last revision of this package leaflet: June 2017
Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS), http://www.aemps.gob.es/